Inclusion Criteria

Patients must have:

• HIV antibody positive.
• CD4 cell counts less than 500/mm3.
• Adequate general health.
• No significant deterioration in performance status within the past month.
• Prior treatment with a stable regimen of antiretroviral medication for at least 4 weeks prior to study.

Prior Medication:

Required:

• Stable regimen of antiretroviral medication for at least 4 weeks prior to study entry.

Allowed:

• Aerosolized pentamidine for PCP prophylaxis.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Intercurrent infection.
• Clinically significant abnormality on EKG.
• Known hypersensitivity to quinolines.
• Known hemoglobin M abnormality.
• Known NADH methemoglobin reductase deficiency.
• Positive test for G6PD deficiency.
• Fever.

Prior Medication:

Excluded:

• Other systemic medication (other than AZT, ddC, ddI, methadone, acyclovir, and NSAIDs) within 3 days prior to study entry.